lncRNA PCAT14 Is a Diagnostic Marker for Prostate Cancer and Is Associated with Immune Cell Infiltration

Figure 2

Relationship between PCAT14 expression and clinically relevant indicators in prostate cancer. (a) Compared with T2 stage prostate cancer, PCAT14 was lowly expressed in T3-4 stage prostate cancer tissues. (b) Compared with N0 stage prostate cancer, PCAT14 was lowly expressed in N1 stage prostate cancer tissues. (c) Compared with M0 stage prostate cancer, PCAT14 was lowly expressed in M1 stage prostate cancer tissue. (d) Compared with the prostate cancer group with -7, PCAT14 was lowly expressed in prostate cancer tissue with -10. (e) PCAT14 was lowly expressed in prostate cancer tissues with the initial treatment outcome of progressive disease, stable disease, and partial response compared with prostate cancer tissues with initial treatment outcome of complete response. (f) PCAT14 was lowly expressed in R1&2 prostate cancer tissue compared with prostate cancer in R0 prostate cancer tissue.

(a)

(b)

(c)

(d)

(e)

(f)